White-Label Telehealth Pricing Models, Explained

Model one: the flat platform fee

A fixed monthly software or platform fee, sometimes tiered by features or volume bands. It is the most legible model: your cost is knowable, the vendor's incentive is retention rather than extraction, and modeling profitability is arithmetic. Self-serve storefront platforms mostly price this way, and some publish their tiers, which is genuinely useful for the category.

The leak to check: what the flat fee does not include. In software-shaped offers, clinical visits, medication, payment processing, and the operating labor of running the clinic all sit on top of the fee. A low platform fee with four pass-through meters behind it is not a low price; it is a distributed one. The flat fee answers 'what does the software cost,' not 'what does a patient cost.'

Model two: per-consult pricing

A fee per completed visit, common wherever clinical capacity is the product: clinician networks, GFE services, and async-visit APIs. It scales cleanly with usage, launches cheap at low volume, and puts the staffing risk on the vendor's side of the table.

The leaks: per-visit costs compound in subscription products (an initial visit plus check-ins plus renewals is several fees per patient per year, so model visits per patient annually, not per transaction), and the consult fee rarely includes the layers around the visit. Per-consult vendors are components; the assembly is still yours.

Model three: the revenue share

The vendor takes a percentage of program revenue, marketed as alignment: they earn when you earn. Sometimes it genuinely is, especially where the vendor funds real operating work and takes the downside with you.

The structural problems: a percentage of revenue is a tax on your growth (your best months are their best months, at your marketing expense), it compounds against scale economics (costs that should flatten per patient instead track revenue upward), and in some strict corporate-practice states, percentage-of-professional-revenue arrangements draw fee-splitting scrutiny, which is a legal-review item, not a pricing preference. The question that cuts through: what does the share buy me that a flat fee would not, and what is the same relationship at my target volume priced both ways?

Run every revenue-share offer through one calculation: at your 24-month target volume, what does the percentage cost per year versus the vendor's flat-fee equivalent? Alignment that survives that arithmetic is real; alignment that does not was a discount on your small months, paid for from your big ones.

Model four: the medication markup

The quietest model, and in recurring-Rx categories often the largest: the vendor (or its pharmacy arrangement) charges you above its fill cost, so the margin lives inside a number you rarely see itemized. Some vendors position against it explicitly, advertising no-markup supply; others build their economics on it while headlining a modest platform fee.

Markup is not inherently illegitimate: someone must be paid for running supply, and a transparent per-fill price can be a fair way to do it. The problem is opacity. In a GLP-1 or hormone program, the per-fill economics multiplied by retention ARE the business, so a markup you cannot see is a P&L you do not control. The two questions that expose it: what exactly do I pay per fill for each product, in writing, and how does that number move if the underlying supply cost moves?

Model five: hybrids, which is most real contracts

Most mature offers stack models: a platform fee plus per-consult fees, a lower fee plus a share, or flat product rates that bundle visit and medication into one per-product number. Hybrids are not a trick; they are how vendors balance fixed and variable economics. The discipline is refusing to evaluate the headline component alone.

The comparison method that works across every model: build the all-in cost per active patient per month at three volumes (launch, 12 months, target), with every meter included: platform, visits, medication, processing, and any share. That one number makes a software fee, a rev share, and a flat product rate directly comparable, which is exactly why some vendors resist producing it. Vendors who build it with you are telling you something too.

• Ask for the all-in per-patient number at three volumes, in writing
• Model visits per patient per YEAR, not per transaction
• Get per-fill medication pricing itemized for every product you will sell
• Price the same relationship both ways before accepting any revenue share
• Check which numbers are fixed in the agreement and which are 'reviewed periodically'

How EmbedCare prices, in this vocabulary

EmbedCare is the hybrid built for legibility: flat product rates fixed in a signed partner agreement, with medication included on GLP-1 programs, so the per-patient number this guide keeps asking for is the actual price. No revenue share, and no per-fill markup mystery, because the pharmacy supply is owned rather than marked up in transit. The self-serve Launch tier starts at $495/mo; you set your retail, and the spread between your retail and the flat rates is yours. A demo prices your specific program in writing, which is the format every number in this category deserves.